Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
Want to see HK:9989 full AI Analyst Report?
9989 Stock Chart & Stats
HK$5.19
HK$0.02(0.54%)
At close: 4:00 PM EST
HK$5.19
HK$0.02(0.54%)
Day’s Range― - ―
52-Week RangeHK$3.80 - HK$7.26
Previous CloseN/A
Volume172.00K
Average Volume (3M)1.16M
Market Cap
HK$13.52B
Enterprise ValueHK$12.30B
Total Cash (Recent Filing)HK$3.50B
Total Debt (Recent Filing)HK$2.79B
Price to Earnings (P/E)33.8
Beta0.97
Next Earnings
Aug 28, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend Yield5.23%
Share Statistics
EPS (TTM)0.26
Shares Outstanding220,094,500
10 Day Avg. Volume947,650
30 Day Avg. Volume1,161,300
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)0.57
Price to Sales (P/S)1.25
P/FCF Ratio4.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.54
Revenue Forecast (FY)HK$6.65B
Bulls Say, Bears Say
Bulls Say
Strong Cash ConversionTTM free cash flow tracking ~93% of net income shows high earnings-to-cash conversion, which supports sustainable funding for operations, R&D, dividends, or debt paydown. Over the next 2–6 months this improves financial flexibility and reduces reliance on external financing.
Moderate Leverage / Solid Balance SheetLow debt-to-equity (~0.18) and a sizable equity base indicate balance-sheet resilience, giving the company capacity to absorb shocks, fund incremental investment, or pursue CDMO contracts without overleveraging. This structural strength supports stability across business cycles.
Focused API And CDMO Revenue MixA business model centered on heparin APIs plus finished-dose products and CDMO services provides diversified revenue streams within a specialized niche. This vertical integration and service offering can sustain recurring contracts and reduce reliance on single-product pricing volatility over time.
Bears Say
Flat To Slightly Down RevenueRevenue stagnation (roughly -1% TTM) coupled with compressed operating profitability versus 2024 suggests limited top-line momentum and weaker pricing power or adverse mix. Persisting flat sales constrain long-term margin expansion and reinvestment capacity across the business.
Uneven Historical Cash And Earnings ConsistencyAlthough current FCF conversion is strong, the company has shown volatile cash generation—negative OCF/FCF in 2021–2022 and weakness in 2023—indicating earnings and cash resilience are uneven. This pattern raises risk that cash performance could revert if conditions worsen.
Muted Returns On EquityLow ROE (~3%) implies the company is currently generating limited shareholder returns from its asset and equity base. Structurally weak profitability relative to capital invested constrains ability to attract capital and signals room for operational efficiency or portfolio improvements over the medium term.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H News
9989 FAQ
What was Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price range in the past 12 months?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H lowest stock price was HK$3.80 and its highest was HK$7.26 in the past 12 months.
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap is HK$13.52B.
When is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date is Aug 28, 2026 which is in 67 days.
How were Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s earnings last quarter?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H released its earnings results on Apr 29, 2026. The company reported HK$0.147 earnings per share for the quarter, beating the consensus estimate of HK$0.126 by HK$0.021.
Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pay dividends?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays a Annually dividend of HK$0.166 which represents an annual dividend yield of 5.23%. See more information on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H dividends here
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate is 0.09.
How many shares outstanding does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H have?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding.
What happened to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price movement after its last earnings report?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H reported an EPS of HK$0.147 in its last earnings report, beating expectations of HK$0.126. Following the earnings report the stock price went down -0.216%.
Which hedge fund is a major shareholder of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9989
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.12%
12-Months-Change
Fundamentals
Return on Equity
3.12%
Trailing 12-Months
Asset Growth
2.57%
Trailing 12-Months
Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Earnings & Revenues
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Sihuan Pharmaceutical Holdings Group
―
China Resources Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---